Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Rima Senvest Ups Its Bet On Axcelis Technologies Inc (ACLS), Should You Follow The Smart Money?

Page 1 of 2

Richard Mishaal‘s Rima Senvest Management acquired an additional 790,600 shares of Axcelis Technologies Inc (NASDAQ:ACLS), according to a recent filing with the Securities and Exchange Commission. The current holding comprises about 6.0 million shares valued at $18.06 million and represents about 5.29% of the company’s outstanding stock. The stock of the $329.99 million manufacturer of processing equipment used in the fabrication of semiconductor chips has appreciated by over 17% so far this year. In contrast, the Semiconductor Equipment & Materials industry has only appreciated by 0.51% during the same period.


Professional money managers, among those that we track, have been increasingly bullish on Axcelis Technologies Inc (NASDAQ:ACLS). A total of 15 hedge funds had an aggregate investment of $26.12 million in the company at the end of March compared with ten firms with $26.92 million in holdings at the end of the previous quarter. The dip in capital is explained by the 7% drop in shares during the first quarter, so hedgies were not actually selling out of the stock. The bullish hedge funds certainly came out ahead with this pick, as it’s gained over 30% since the end of the first quarter.

Richard Mashaal
Richard Mashaal
Rima Senvest Management

First a quick word on why we track hedge fund activity. In 2014, equity hedge funds returned just 1.4%. In 2013, that figure was 11.3%, and in 2012, they returned just 4.8%. These are embarrassingly low figures compared to the S&P 500 ETF (SPY)’s 13.5% gain in 2014, 32.3% gain in 2013, and 16% gain in 2012. Does this mean that hedge fund managers are dumber than a bucket of rocks when it comes to picking stocks? The answer is definitely no. Our small-cap hedge fund strategy, which identifies the best small-cap stock picks of the best hedge fund managers returned 28.2% in 2014, 53.2% in 2013, and 33.3% in 2012, outperforming the market each year (it’s outperforming it so far in 2015 too). What’s the reason for this discrepancy you may ask? The reason is simple: size. Hedge funds have gotten so large, they have to allocate the majority of their money into large-cap liquid stocks that are more efficiently priced. They are like mutual funds now. Consider Ray Dalio’s Bridgewater Associates, the largest in the industry with about $165 billion in AUM. It can’t allocate too much money into a small-cap stock as merely obtaining 2% exposure would really move the price. In fact, Dalio can’t even obtain 2% exposure to many small-cap stocks, even if he essentially owned the entire company, as they’re simply too small (or rather, his fund is too big). This is where we come in. Our research has shown that it is actually hedge funds’ small-cap picks that are their best performing ones and we have consistently identified the best picks of the best managers, returning 135% since the launch of our small-cap strategy compared to less than 60% for the S&P 500 (see the details).

Insider trading activity can provide valuable insights into the expectations of  a company’s management with regards to its future prospects. Although no insider purchases have been made this year, there has been some insider selling during the last six months, including by Lynnette Fallon, Axcelis’ Executive Vice President, who sold about 124,000 shares, and by Chief Financial Officer Kevin Brewer, who sold 71,000 shares. However, unlike insider purchases, insider sales do not provide a clear picture of the company’s prospects since they can be carried out for a wide variety of reasons.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!